Resistant Hypertension (RHT) Clinical Trial
Do you or a loved one live with Resistant Hypertension (HRT) or High Blood Pressure (HBP)?
You may be eligible to participate in this study.
Do you or a loved one live with Resistant Hypertension (HRT) or High Blood Pressure (HBP)? You may be eligible to participate in this study.
Aalborg University Hospital Cardiology
Active not recruiting Aalborg, DNK 9000
Aberdeen Royal Infirmary Clinical Pharmacology Unit
Active not recruiting Aberdeen, GBR AB24 2ZN
Active not recruiting Afula, ISR 1834111
Albany Medical College
Active not recruiting 43 New Scotland Avenue, Albany, NY, USA 12208
Renal Medicine Associates
Active not recruiting 3821 Masthead Street Northeast, Albuquerque, NM, USA 87109
Advanced Cardiovascular LLC
Active not recruiting 1649 Alabama 22, Alexander City, AL, USA 35010
Alexandria Cardiology Clinic
Active not recruiting 501 Medical Center Drive, Alexandria, LA, USA 71301
Amarillo Heart Clinical Research Institute Inc
Active not recruiting 1901 Port Lane, Amarillo, TX, USA 79106
Academic Medical Center Amsterdam
Active not recruiting Amsterdam, NLD 1105 AZ
Details for the study
Treatments and/or Procedures
Inclusion Criteria: Screening period: - Signed and dated ICF prior to any study-mandated procedure; - Male and female subjects; 18 years (or year of country specific majority) or older; - Historical documentation in the subject's medical records on uncontrolled BP despite at least 3 background antihypertensive medications within 1 year before screening visit; - Treated with at least 3 antihypertensive therapies of different pharmacological classes for at least 4 weeks before the screening visit (Visit 1); - Mean SiSBP ≥ 140 mmHg measured by AOBPM; - Women of childbearing potential are eligible only if the following applies; - Negative pregnancy test at screening and at baseline (i.e., before randomization); - Agreement to undertake pregnancy tests during the study and up to 30 days after randomized study treatment discontinuation; - Agreement to use methods of birth control from Screening up to at least 30 days after randomized study treatment discontinuation. Run-in period (RI): - Switched to the standardized background antihypertensive therapy at least 4 weeks before the first RI visit; - Mean trough SiSBP ≥ 140 mmHg as measured by AOBPM. Randomization period: - Stable dose of the standardized background antihypertensive therapy for at least 1 week before the end of the RI period; - Mean trough SiSBP ≥ 140 mmHg measured by AOBPM. Exclusion Criteria: - Apparent/pseudo RHT due to white coat effect, medical inertia, poor therapeutic adherence, or secondary causes of hypertension (except sleep apnea); - Confirmed severe hypertension (grade 3) defined as SiSBP≥180 mmHg and/or SiDBP≥110 mmHg as measured by AOBPM at two different timepoints; - Pregnant or lactating subjects; - Clinically significant unstable cardiac disease at screening or in the past in the opinion of the investigator (exclusion of participants with significant or potential unstable cardiac disease); - Severe renal insufficiency; - Any known factor, disease or clinically relevant medical or surgical conditions that, in the opinion of the investigator, might put the subject at risk, interfere with treatment compliance, study conduct or interpretation of the results. - Treatment with any medication which may affect BP and/or treatment with high dose of loop diuretics (i.e., furosemide greater than 80 mg/day, or equivalent dosage of other loop diuretics).